TRANSLATION TO CLINIC CONCURRENT Progress and Challenges with Gene Editing
Thursday, June 1, 2023 05:00 PM - 06:00 PM
252AB
TRANSLATION TO CLINIC
Concurrent
Chair
Patrick Hanley, PhD, Chief and Director, Cellular Therapy Program Associate Professor of Pediatrics, Children's National Hospital, USA
Speakers
Mick Fellows, PhD, Senior Director Biopharma Cell Therapy Safety, AstraZeneca, UK
Paula Rio, PhD, Head of the Bone Marrow Aplasia Unit of the Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Spain
Shin Kaneko, MD, PhD, Professor/Deputy Director, Kyoto University, Japan
Session Description
In this session we will hear about progress being made with gene editing and how this advancement is uniquely poised to benefit the cell and gene therapy field. This program will include an assessment of CRISPR-Cas9 induced off-target mutagenesis in gene edited cellular therapeutics, a presentation about how gene editing can unlock the potential of iPS cells and cytotoxic T cells and CAR T, and how gene editing can be exploited to correct hematopoietic stem cells in patients with blood disorders.
Patrick Hanley, PhD, Chief and Director, Cellular Therapy Program Associate Professor of Pediatrics, Children's National Hospital, USA
Speakers
Mick Fellows, PhD, Senior Director Biopharma Cell Therapy Safety, AstraZeneca, UK
Paula Rio, PhD, Head of the Bone Marrow Aplasia Unit of the Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Spain
Shin Kaneko, MD, PhD, Professor/Deputy Director, Kyoto University, Japan
Session Description
In this session we will hear about progress being made with gene editing and how this advancement is uniquely poised to benefit the cell and gene therapy field. This program will include an assessment of CRISPR-Cas9 induced off-target mutagenesis in gene edited cellular therapeutics, a presentation about how gene editing can unlock the potential of iPS cells and cytotoxic T cells and CAR T, and how gene editing can be exploited to correct hematopoietic stem cells in patients with blood disorders.
Patrick Hanley PhD
Chief and Director, Cellular Therapy Program Associate Professor of Pediatrics
Children's National Hopital
Chair
Chief and Director, Cellular Therapy Program Associate Professor of Pediatrics
Children's National Hopital
Chair
Paula Rio PhD
Head of the Bone Marrow Aplasia Unit of the Hematopoietic Innovative Therapies Division
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas
Speaker
Head of the Bone Marrow Aplasia Unit of the Hematopoietic Innovative Therapies Division
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas
Speaker